Satellite TV

HUYA Bioscience International Licenses the Novel SHP2 Inhibitor HBI-2376 for Development in Oncology

Chief Editor August 4, 2020 0 10 sec read
SAN DIEGO Aug. 4, 2020 /PRNewswire/ — HUYA Bioscience International (HUYABIO ), the leader in accelerating global development of China’s pharmaceutical innovations, announced today it has exclusively licensed worldwide rights, outside of China , to the SHP2 inhibitor, HBI-2376, from Suzhou GenHouse.


Read all

Chief Editor

View More Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Guangzhou’s new airport terminal opens as passenger numbers soar

Guangzhou’s new 17 billion yuan (US$2.7 billion) airport terminal opened on Thursday, designed to handle 100 million passengers a year from southern China’s “Greater Bay […]

April 26, 2018 0 13 sec read

S. African government condemns terrorist attacks in Belgium

CAPE TOWN, March 24 (Xinhua) — The South African government on Thursday joined the international community in strongly condemning the terrorist attacks in Brussels, Belgium. […]

March 24, 2016 0 12 sec read

New Czech Republic airport targets 2020 opening

The New Budweis International Airport, located in the South Bohemian region in the Czech Republic, is eyeing a 2020 opening with plans to begin scheduled […]

August 16, 2018 0 10 sec read

TNB takes control of one of UK’s largest solar panel platforms

KUALA LUMPUR: Tenaga Nasional Bhd’s (TNB) wholly-owned subsidiary, TNB International Sdn Bhd (TNBI) has acquired the controlling equity stake in Vortex Solar Investments S.a.r.l. (Vortex […]

September 17, 2020 0 14 sec read